Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Interim Impact The Rise of Fractional Medical Affairs Roles in Pharmas New Reality
Summary
In this episode, Tom Caravela and Daniel Snyder explore the rise of fractional medical affairs roles in the post-COVID era. They define interim and fractional positions, highlighting how they benefit both job seekers and companies. The discussion covers the increase in these roles, company utilization of interim talent, disadvantages, and compensation expectations, offering negotiation tips for candidates. They also discuss the future of fractional staffing, market trends, and the gig economy's impact on pharma and biotech. The episode ends with cost-effective strategies and gratitude to the audience.
Key Points
- Fractional medical affairs roles offer a cost-effective solution for pharmaceutical companies to address specific project needs without committing to full-time hires. The rise in fractional positions is driven by economic uncertainties and the need for companies to streamline operations while still advancing critical projects. Engaging in fractional work can help professionals bridge employment gaps, expand their networks, and gain new therapeutic experience, making them more attractive in the job market.
fractional medical affairs roles, interim positions, gig economy in pharma, pharmaceutical staffing trends, fractional work benefits
Related Topics
You May Also Like
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Podcast
Michael Pietrack
Hiring Managers Beware: Reverse Rejection Explained!
Article
Jamie Riley
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Forbes Books Press Release Official
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
Podcast
MSL Talk: Tom Caravela, Josh Corriveau